Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + interferon
- Development stage
- Unknown
- Lead developer
- Bayer Pharmaceuticals
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
Sorafenib + interferon is a combination therapy consisting of the small molecule multikinase inhibitor sorafenib and an immunomodulatory cytokine, typically interferon alpha (either alpha-2a or alpha-2b). Sorafenib inhibits tumor cell proliferation by blocking the RAF/MEK/ERK pathway and reduces angiogenesis by inhibiting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) signaling. Interferon-alpha exerts antitumor effects primarily through antiangiogenic activity and immune regulation. This combination has been investigated in clinical trials for advanced renal cell carcinoma (RCC) and melanoma, showing preliminary antitumor activity with manageable toxicity profiles[1][2][5]. The combination is not approved as a standard regimen but has demonstrated efficacy in phase I/II studies.
- Brand names
- Nexavar (for sorafenib)
- Other names
- sorafenib plus interferon-alphasorafenib + IFN-alpha
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)FGFR1 (Fibroblast growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)IFNAR (Immune system modulation via type I interferon receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MAPK14 (p38 mitogen-activated protein kinase alpha)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)RUVBL2 (RuvB-like AAA ATPase 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sorafenib + interferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + interferon.